Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition

Elena Makino(University of Tübingen), Birgit Schittek(University of Tübingen)

Cell Death and Disease

July 2, 2020

10.1038/s41419-020-2702-y

Cited by 29

Related Papers

Examination of Regional Lymph Nodes by Sentinel Node Biopsy and Molecular Analysis Provides New Staging Facilities in Primary Cutaneous Melanoma

|Journal of Investigative Dermatology|2000|183

β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance

|PLoS ONE|2011|108

Detection of Melanoma Micrometastasis in Sentinel Nodes by Reverse Transcription-Polymerase Chain Reaction Correlates With Tumor Thickness and Is Predictive of Micrometastatic Disease in the Lymph Node Basin

|The American Journal of Surgical Pathology|1999|82

Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness

|British Journal of Dermatology|2001|50

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase

|Oncotarget|2017|48